← Back to patent-cliff list
RX-0301
Tier C — Watch / tradeRX-0301
Rexahn Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：AKT1
Brand：Mychexin
Indications (approved)：Hepatocellular carcinoma, Renal cell carcinoma, Liver cancer, Solid tumour
Regional status
US
Phase II
2024-02-14
EU
-
China
Phase II
2024-07-05
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RX-0301?
Approved indications include: Hepatocellular carcinoma, Renal cell carcinoma, Liver cancer, Solid tumour.
When does the RX-0301 patent expire?
No public expiry year is available for RX-0301 yet; this page updates once verified.
How do I get a quote for RX-0301 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01